Shots:
- Takeda reported the EMA’s approval of an additional 2 mL pre-filled pen option for Takhzyro (lanadelumab) for patients aged ≥12 with Recurrent hereditary angioedema (HAE)
- Currently Takhzyro is approved in 150 mg and 300 mg pre-filled syringes and 300 mg vial. The new approval is for a 300 mg pre-filled pen (2 mL solution) that was supported by a clinical study
- Takhzyro is a fully human mAb that targets and inhibits plasma kallikrein, indicated for the routine prevention of recurrent HAE attacks in patients aged 2 yrs. and older
Ref: Takeda | Image: Takeda
Related News:- Takeda Receives Health Canada’s Approval for Fruzaqla (fruquintinib) to Treat Metastatic Colorectal Cancer (mCRC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
